Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Galapagos 100 euro per aandeel

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,920   +0,160   (+0,62%) Dagrange 25,840 - 26,160 30.781   Gem. (3M) 87,8K

Galapagos 100 euro per aandeel

Volgen
1.208 Posts
Pagina: «« 1 ... 25 26 27 28 29 ... 61 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 januari 2017 23:07
    Branchegenoot van Galapagos maakt geld.

    VERTEX
    Full-Year 2016 Financial Highlights Revenues:
    • Total CF revenues were $1.68 billion compared to $982.3 million for 2015.
    • Net product revenues from ORKAMBI were $979.6 million compared to $350.7 million for 2015 . ORKAMBI was launched
    in the U.S. in July 2015.
    • Net product revenues from KALYDECO were $703.4 million compared to $631.7 million for 2015 .

    GAAP net loss was $(112.1) million , or $(0.46) per diluted share, compared to Vertex's 2015 GAAP net loss of $(556.3) million , or $(2.31) per diluted share. Non-GAAP net income was $211.2 million , or $0.85 per diluted share, compared to a non-GAAP net loss of $(267.3) million , or $(1.11) per diluted share, for 2015 . The decreased net loss on a GAAP basis and the change to net income on a non-GAAP basis was the result of a full year of ORKAMBI product revenues and increased KALYDECO product revenues, partially offset by increased operating expenses.

    files.shareholder.com/downloads/VRTX/...

    Koers 100 euro Galapagos dichter bij, dan menigeen denkt.
  2. [verwijderd] 26 januari 2017 08:43
    quote:

    inspirator schreef op 25 januari 2017 23:07:

    Branchegenoot van Galapagos maakt geld.

    VERTEX
    Full-Year 2016 Financial Highlights Revenues:
    • Total CF revenues were $1.68 billion compared to $982.3 million for 2015.
    • Net product revenues from ORKAMBI were $979.6 million compared to $350.7 million for 2015 . ORKAMBI was launched
    in the U.S. in July 2015.
    • Net product revenues from KALYDECO were $703.4 million compared to $631.7 million for 2015 .

    GAAP net loss was $(112.1) million , or $(0.46) per diluted share, compared to Vertex's 2015 GAAP net loss of $(556.3) million , or $(2.31) per diluted share. Non-GAAP net income was $211.2 million , or $0.85 per diluted share, compared to a non-GAAP net loss of $(267.3) million , or $(1.11) per diluted share, for 2015 . The decreased net loss on a GAAP basis and the change to net income on a non-GAAP basis was the result of a full year of ORKAMBI product revenues and increased KALYDECO product revenues, partially offset by increased operating expenses.

    files.shareholder.com/downloads/VRTX/...

    Koers 100 euro Galapagos dichter bij, dan menigeen denkt.

    Forget Incyte: Gilead Sciences Would Be Better Off Buying 'Galapagos'

    Read more: www.fool.com/investing/2017/01/25/for...

    Galapagos looks like a steal

    Compared to Incyte, Galapagos is relatively cheap at just $3.2 billion. That's a reasonable valuation for a company without a product on the market. But if Gilead Sciences is looking for products that could reach market quickly, or a large influx of new shots on goal, then it would be difficult to find a better target than Galapagos.

    The Belgium biotech boasts one phase 3 trial, four phase 2 trials, three phase 1 trials, five preclinical trials, and 20 discovery programs. That includes programs for osteoarthritis and cystic fibrosis, partnered with Servier and AbbVie , respectively. Its most advanced drug candidate, a JAK1 inhibitor called filgotinib, is partnered with Gilead Sciences in three separate trials targeting rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

    The collaboration didn't come cheap. Gilead Sciences paid $300 million up front and made a $425 million equity investment in the innovative upstart. Galapagos is also entitled to receive milestone payments of up to $755 million, sales-based milestone payments of up to $600 million, and tiered royalties on global sales that start at 20%. That's a lot of dough, partially because the market opportunity for the three autoimmune diseases is enormous. The global markets for ulcerative colitis and Crohn's disease alone are expected to reach a combined $11 billion by 2022.

    The growth potential is impressive for successful therapies -- and so are the potential milestone payments. Luckily, Gilead Sciences' equity investment may prove strategic. How so? It means the Hepatitis C pioneer now owns 14.7% of Galapagos, which would make any potential acquisition 14.7% cheaper. If the company's pipeline heats up and other biopharmas start inquiring about an acquisition, then Gilead Sciences owns a sweet bidding advantage over its peers.

    Read more: www.fool.com/investing/2017/01/25/for...

  4. [verwijderd] 30 januari 2017 20:09
    One of those drugs is filgotinib, an autoimmune disease drug Gilead Sciences is co-developing with Galapagos NV. Filgotinib recently entered phase 3 studies for use in rheumatoid arthritis, Crohn's disease, and ulcerative colitis. A clean safety profile in mid-stage studies and oral dosing could make it a top-seller someday.

    Ready to make a deal
    Keith Speights: For those who think Gilead's future looks dim, remember that the biotech's stock nearly tripled over the past five years primarily because of an acquisition. Back in November 2011, Gilead bought Pharmasset for $11 billion, picking up the hepatitis C virus (HCV) drug later to be known as Sovaldi. Combinations of Sovaldi with other drugs led to the successful commercial launches of two other HCV drugs, Harvoni and Epclusa.

    Gilead has more money -- and more motivation -- to make a game-changing acquisition than it did a little over five years ago. The biotech reported $31.6 billion in cash, cash equivalents, and marketable securities at the end of the third quarter of 2016. With its strong operating cash flow, Gilead undoubtedly has more than that now.

    CEO John Milligan has publicly stated that the company is focused on "augmenting [its] portfolio with external opportunities, particularly in the field of oncology." However, Milligan didn't limit Gilead's acquisition prospects to only oncology.

    I don't expect the biotech to merely throw money at an acquisition in the hopes that it pays off; Gilead's management team is too disciplined to make a rash decision. However, it won't surprise me if Gilead makes one or more deals in 2017 that pay off for investors over the long run.

    www.fool.com/investing/2017/01/30/why...
  6. [verwijderd] 29 maart 2017 16:55
    quote:

    springinhetveld schreef op 4 maart 2016 17:02:

    Die "inspirator" toch. Vorig jaar had hij ook zo een leuk fantasie draadje:
    "koers MDxHealth naar 15,25 en later naar 47 euro"

    Die staan momenteel op 3,50 (komen net van 2,90). Weet niet wat er mis is met deze jonge of wat hij er mee wil berijken. Heeft iig een zeer levendige fantasie en is zeer positief ingesteld. Maar om nou veel waarde aan zijn woorden te hechten......nö geloof niet dat dat verstandig is.

    Erkenning komt pas later !
  8. forum rang 10 voda 29 maart 2017 21:10
    quote:

    inspirator schreef op 4 maart 2016 01:01:

    Overvolle pijplijn Galapagos met 1,2 miljard cash.

    Stijging koers Galapagos naar 100 euro in verschiet.
    Zat je er toen in Inspirator? (en tegen welke koers?)

    De slotkoers toen, 4 maart 2016 was 40.50.

    Bijna een verdubbeling in 1 jaar tijd!

    www.iex.nl/Aandeel-Koers/60189120/Gal...
1.208 Posts
Pagina: «« 1 ... 25 26 27 28 29 ... 61 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Galapagos: bemoedigende nieuwe resultaten met recidief/refractair non-Hodgkin lymfoom
  2. Kepler Cheuvreux zet Galapagos op verkooplijst
  3. Klinische resultaten Galapagos steunen celtherapie-hypothese
  4. Deutsche Bank verlaagt koersdoel Galapagos
  5. Financials en Shell doen goede zaken op terughoudend Damrak
  6. Galapagos herhaalt cash burn voor 2024
  7. Galapagos benoemt investeerder Nodelman in bestuur
  8. EcoR1 nog groter in Galapagos
  9. EcoR1 groter in Galapagos
  10. FMR LLC kleiner in Galapagos